NOVAVAX INC Convertible Notes Payable, Noncurrent
NOVAVAX INC (NVAX) had Convertible Notes Payable, Noncurrent of $244.21 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:ConvertibleLongTermNotesPayable · last filed 2026-02-26
- 2025-12-31: Convertible Notes Payable, Noncurrent $244.21M.
- 2025-09-30: Convertible Notes Payable, Noncurrent $243.84M.
- 2025-06-30: Convertible Notes Payable, Noncurrent $170.57M.
- 2025-03-31: Convertible Notes Payable, Noncurrent $170.13M.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2025-12-31 | $244.21M 10-K · filed 2026-02-26 |
| 2025-09-30 | $243.84M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $170.57M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $170.13M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $169.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | $169.26M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $168.85M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $168.43M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $168.02M 10-K · filed 2025-02-27 |
| 2023-09-30 | $167.62M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $167.25M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $166.86M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $166.47M 10-K · filed 2024-02-28 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 |
| 2021-12-31 | $323.46M 10-K · filed 2023-02-28 |
| 2021-09-30 | $323.10M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $322.75M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $322.39M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $322.04M 10-K · filed 2022-03-01 |
| 2020-09-30 | $321.68M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $321.32M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $320.97M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $320.61M 10-K · filed 2021-03-01 |
| 2019-09-30 | $320.25M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $319.90M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $319.54M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $319.19M 10-K · filed 2020-03-11 |
| 2018-09-30 | $318.83M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $318.48M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $318.12M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $317.76M 10-K · filed 2019-03-18 |
| 2017-09-30 | $317.41M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $317.05M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $316.69M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $316.34M 10-K · filed 2018-03-14 |
| 2016-09-30 | $315.98M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $315.63M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $315.27M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $0.00 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |